Michael Dixon, Richard Nixon, James O'Neill, Nick Venters
{"title":"Raised Creatine Kinase with Numerous Antipsychotics Responded to Clozapine.","authors":"Michael Dixon, Richard Nixon, James O'Neill, Nick Venters","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>There is much uncertainty on continuing antipsychotics where a patient has an asymptomatic rise in creatine kinase. This case report describes a patient in his late 20s and early 30s with an established diagnosis of schizophrenia. He experienced multiple asymptomatic rises in creatine kinase (CK) when treated with numerous antipsychotics, which led to them being discontinued. Eventually, successful treatment was undertaken when clozapine was trialled. This led to improved quality of life scores when objectively measured, as well as good tolerance with no physical health sequelae. In conclusion, we recommend that clozapine is considered when other antipsychotic medications lead to elevated CK levels or neuroleptic malignant syndrome.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 2","pages":"85-93"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809504/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
There is much uncertainty on continuing antipsychotics where a patient has an asymptomatic rise in creatine kinase. This case report describes a patient in his late 20s and early 30s with an established diagnosis of schizophrenia. He experienced multiple asymptomatic rises in creatine kinase (CK) when treated with numerous antipsychotics, which led to them being discontinued. Eventually, successful treatment was undertaken when clozapine was trialled. This led to improved quality of life scores when objectively measured, as well as good tolerance with no physical health sequelae. In conclusion, we recommend that clozapine is considered when other antipsychotic medications lead to elevated CK levels or neuroleptic malignant syndrome.